Oric Pharmaceuticals, Inc. — Director's Dealing 2022

May 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2022-05-11

Reporting Person: Chacko Jacob (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-11	Common Stock	P	304574	$2.901	Acquired	657226	Direct
2022-05-12	Common Stock	P	69354	$2.7463	Acquired	726580	Direct
2022-05-13	Common Stock	P	76072	$2.8205	Acquired	802652	Direct

Footnotes

F1: Represents the weighted average share price of an aggregate total of 304,574 shares purchased in the price range of $2.695 to $2.95 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average share price of an aggregate total of 69,354 shares purchased in the price range of $2.70 to $2.77 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average share price of an aggregate total of 76,072 shares purchased in the price range of $2.79 to $2.93 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.